Pharmaceutical

Candid Therapeutics signs $925m T cell engager deal with WuXi Biologics

Candid plans to conduct first-in-human studies in 2026 as it continues its T-cell engager deal drive.

Jan 8, 2025 - 06:00
Candid Therapeutics signs $925m T cell engager deal with WuXi Biologics
Candid plans to conduct first-in-human studies in 2026 as it continues its T-cell engager deal drive.
Read the original article

Tags:

Previous Article

Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment

Next Article

WuXi Biologics to sell Ireland-based vaccine site to MSD for $500m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How a supplement company became a haven for health misinformation

How a supplement company became a haven for health misi...

Sep 8, 2023

J&J expands dermatology portfolio with $850m Proteologix acquisition

J&J expands dermatology portfolio with $850m Proteologi...

May 19, 2024

Kymera’s novel MDM2 degrader granted orphan designation for AML

Kymera’s novel MDM2 degrader granted orphan designation...

Jun 23, 2023